ADAM17 and non-small cell lung carcinoma: Using non-small-cell lung carcinoma (NSCLC) and patient-derived xenografts, as well as the KrasG12D mouse model, Saad et al. showed that depletion of ADAM17, or inhibition of its activity, suppressed lung tumour growth.